2-fluoro-4-methoxybenzaldehyde oxime | 348-24-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-fluoro-4-methoxybenzaldehyde oxime
• 英文别名: 2-Fluoro-4-methoxybenzaldehyde oxime；N-[(2-fluoro-4-methoxyphenyl)methylidene]hydroxylamine
• CAS: 348-24-3
• 化学式: C₈H₈FNO₂
• 分子量: 169.155
• InChiKey: IWVMSNIWGPNWIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-fluoro-4-methoxybenzaldehyde oxime 在 N-氯代丁二酰亚胺 、 potassium tert-butylate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-methoxy-N-(2-methyl-2-phenylpropyl)-1,2-benzoxazol-3-amine
  参考文献：
  名称：

  Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors

  摘要：

  Phenethylaminoheterocycles have been prepared and assayed for inhibition of the K(v)1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. A diverse set of heterocycles were identified as potent K(v)1.5 inhibitors and were advanced to pharmacodynamic evaluation based on selectivity and pharmacokinetic profile. Heterocycle optimization and template modification lead to the identification of compound 24 which demonstrated increased atrial effective refractory period in the rabbit pharmacodynamic model with mild effects on blood pressure and heart rate. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.035
• 作为产物：
  描述：

  2-氟-4-甲氧基苯甲醛 在 盐酸羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 2.5h， 以90%的产率得到2-fluoro-4-methoxybenzaldehyde oxime
  参考文献：
  名称：

  [EN] GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS
  [FR] COMPOSÉS D'AMINOBENZISOXAZOLE À SUBSTITUTION GÉMINALE UTILISÉS EN TANT QU'AGONISTES DE RÉCEPTEURS DE L'ACÉTYLCHOLINE Α7-NICOTINIQUE

  摘要：

  本发明涉及新型的双取代氨基苯并异噁唑化合物，以及适用作α7- nAChR激动剂或部分激动剂的药物组合物，以及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物，特别是将该化合物或组合物用于需要的患者的给药方法，例如患有认知缺陷和/或希望增强认知功能的患者，可能从中获益。

  公开号：

  WO2017027600A1

文献信息

• SULFONAMIDE DERIVATIVE AND USE THEREOF
  申请人：Fukumoto Shoji

  公开号：US20140024650A1

  公开（公告）日：2014-01-23

  Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

  提供了一种具有AMPA受体功能增强作用的化合物，可用作预防或治疗抑郁症、阿尔茨海默病、精神分裂症、注意力缺陷多动障碍（ADHD）等药物。该化合物由式（I）表示：其中每个符号如本说明书所定义，或其盐。
• Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents
  作者：Laura A. McAllister、Justin I. Montgomery、Joseph A. Abramite、Usa Reilly、Matthew F. Brown、Jinshan M. Chen、Rose A. Barham、Ye Che、Seung Won Chung、Carol A. Menard、Mark Mitton-Fry、Lisa M. Mullins、Mark C. Noe、John P. O’Donnell、Robert M. Oliver、Joseph B. Penzien、Mark Plummer、Loren M. Price、Veerabahu Shanmugasundaram、Andrew P. Tomaras、Daniel P. Uccello

  DOI：10.1016/j.bmcl.2012.09.058

  日期：2012.11

  The synthesis and antibacterial activity of heterocyclic methylsulfone hydroxamates is presented. Compounds in this series are potent inhibitors of the LpxC enzyme, a key enzyme involved in the production of lipopolysaccharide (LPS) found in the outer membrane of Gram-negative bacteria. SAR evaluation of compounds in this series revealed analogs with potent antibacterial activity against challenging Gram-negative species such as Pseudomonas aeruginosa and Klebsiella pneumoniae. (C) 2012 Elsevier Ltd. All rights reserved.
• Design, synthesis and evaluation of phenethylaminoheterocycles as Kv1.5 inhibitors
  作者：James A. Johnson、Ningning Xu、Yoon Jeon、Heather J. Finlay、Alexander Kover、Mary L. Conder、Huabin Sun、Danshi Li、Paul Levesque、Mei-Mann Hsueh、Timothy W. Harper、Ruth R. Wexler、John Lloyd

  DOI：10.1016/j.bmcl.2014.05.035

  日期：2014.7

  Phenethylaminoheterocycles have been prepared and assayed for inhibition of the K(v)1.5 potassium ion channel as a potential approach to the treatment of atrial fibrillation. A diverse set of heterocycles were identified as potent K(v)1.5 inhibitors and were advanced to pharmacodynamic evaluation based on selectivity and pharmacokinetic profile. Heterocycle optimization and template modification lead to the identification of compound 24 which demonstrated increased atrial effective refractory period in the rabbit pharmacodynamic model with mild effects on blood pressure and heart rate. (C) 2014 Elsevier Ltd. All rights reserved.
• [EN] GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSÉS D'AMINOBENZISOXAZOLE À SUBSTITUTION GÉMINALE UTILISÉS EN TANT QU'AGONISTES DE RÉCEPTEURS DE L'ACÉTYLCHOLINE Α7-NICOTINIQUE
  申请人：FORUM PHARMACEUTICALS INC

  公开号：WO2017027600A1

  公开（公告）日：2017-02-16

  The present invention relates to novel geminal substituted aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

  本发明涉及新型的双取代氨基苯并异噁唑化合物，以及适用作α7- nAChR激动剂或部分激动剂的药物组合物，以及制备这些化合物和组合物的方法，以及在维持、治疗和/或改善认知功能的方法中使用这些化合物和组合物，特别是将该化合物或组合物用于需要的患者的给药方法，例如患有认知缺陷和/或希望增强认知功能的患者，可能从中获益。